---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-227626"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2023-09-01T23:59:59+00:00"
generated_at: "2026-06-11T00:24:01.648945+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics enters $50M at-the-market equity offering with Cantor Fitzgerald

## Summary
- Enters Controlled Equity Offering Sales Agreement to sell up to $50.0M of common stock through Cantor Fitzgerald.
- Shares sold in at-the-market offerings; Cantor receives 3.0% commission on gross proceeds.
- Company has no obligation to sell any shares and may suspend or terminate offering at any time.
- Offering registered under existing S-3 shelf; prospectus supplement filed September 1, 2023.

## SEC filing metadata
- accession: 0001193125-23-227626
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2023-09-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000119312523227626/0001193125-23-227626-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000119312523227626/d498636d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-227626
- JSON: https://secwatch.observer/filing/0001193125-23-227626.json
- Plain text: https://secwatch.observer/filing/0001193125-23-227626.txt

## Key facts
- Material Agreements
  Lyra Therapeutics, Inc. entered into Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. valued at $50.0 million (effective 2023-09-01).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Cantor Fitzgerald & Co.
  - Value: $50.0 million
  - Effective: 2023-09-01
  source text: On September 1, 2023, Lyra Therapeutics, Inc. (the “Company”) entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) pursuant to which the Company may offer and sell, from time to time through Cantor, shares of the Company’s common stock, par value $0.001 per share (“Common Stock”), for aggregate gross proceeds of up to $50.0 million (the “Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1327273/000119312523227626/0001193125-23-227626-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.